Serina Therapeutics Advances SER-252 Phase 1b Study to Cohort 2

What Happened

• On September 9, 2026, Serina Therapeutics, Inc. (SER) announced that the Independent Safety Monitoring Committee (ISMC) completed a blinded review of Cohort 1 in its ongoing Phase 1b registrational study of SER-252 for advanced Parkinson’s disease and recommended the study advance to Cohort 2.
• Cohort 1 evaluated the lowest dose in the single-ascending-dose portion and showed a pharmacokinetic profile consistent with the sustained apomorphine exposure SER-252 is designed to provide, along with sustained periods of motor improvement in individual patients on exploratory clinical measures. The company expects to report topline data from the single-ascending-dose portion in the first half of 2027. (Press release attached as Exhibit 99.1.)

Key Details

• Date: September 9, 2026 — Company issued press release and filed Form 8-K.
• Review outcome: ISMC completed a blinded review of Cohort 1 and recommended advancement to Cohort 2.
• Cohort 1 findings: Pharmacokinetics consistent with sustained apomorphine exposure; exploratory measures showed sustained motor improvements in individual patients.
• Next data milestone: Topline results from the single-ascending-dose portion expected in H1 2027.

Why It Matters

• Advancement to Cohort 2 signals an initial favorable safety/PK review by the ISMC and preserves the study’s planned dose-escalation timeline, which is a near-term operational milestone for the program.
• Topline data expected in H1 2027 represents a potential catalyst that could provide broader insight into SER-252’s clinical profile.
• This is early clinical-stage news (Phase 1b); while encouraging, these are preliminary findings from a small cohort and not proof of efficacy or eventual regulatory approval.